Literature DB >> 24074948

An acquired, calcium-dependent, factor X inhibitor.

George J Broze1.   

Abstract

Acquired factor X (FX) deficiency unrelated to amyloidosis is a rare disorder in which an anti-FX antibody is infrequently detected. A patient with severe bleeding due to a calcium ion-dependent anti-FX IgG antibody is described. The FX affinity purified IgG bound the light chain of FX, but not FX lacking its γ-carboxyglutamic acid domain, and binding was enhanced >1000-fold in the presence of calcium ions. The antibody also recognized prothrombin and factor VII with about 100-fold and 1000-fold lower affinity. Like a lupus anticoagulant, increasing concentrations of phospholipids in functional assays reduced the inhibitory activity of the antibody. The effect of these properties of the inhibitor on laboratory diagnostic studies is considered.
© 2013.

Entities:  

Keywords:  Acquired; Calcium-dependent; Factor X; Inhibitor

Mesh:

Substances:

Year:  2013        PMID: 24074948      PMCID: PMC3947207          DOI: 10.1016/j.bcmd.2013.09.001

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  8 in total

1.  The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition.

Authors:  Matthew Ndonwi; Elodee A Tuley; George J Broze
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

Review 2.  Acquired, non-amyloid related factor X deficiency: review of the literature.

Authors:  G Lee; W Duan-Porter; Ara D Metjian
Journal:  Haemophilia       Date:  2012-09       Impact factor: 4.287

Review 3.  Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity.

Authors:  Benny Sørensen; Donat R Spahn; Petra Innerhofer; Michael Spannagl; Rolf Rossaint
Journal:  Crit Care       Date:  2011-01-12       Impact factor: 9.097

4.  Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis.

Authors:  A D Mumford; J O'Donnell; J D Gillmore; R A Manning; P N Hawkins; M Laffan
Journal:  Br J Haematol       Date:  2000-08       Impact factor: 6.998

5.  Successful treatment of transient acquired factor X deficiency by plasmapheresis with concomitant intravenous immunoglobulin and steroid therapy.

Authors:  S V Smith; D K Liles; G C White; M E Brecher
Journal:  Am J Hematol       Date:  1998-03       Impact factor: 10.047

6.  A unique circulating inhibitor with specificity for coagulation factor X.

Authors:  M W Lankiewicz; W R Bell
Journal:  Am J Med       Date:  1992-09       Impact factor: 4.965

7.  Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complications.

Authors:  Aneel A Ashrani; Agnes Aysola; Hani Al-Khatib; William L Nichols; Nigel S Key
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

8.  Factor X inhibitor: a fulminant presentation and fatal course of a rare syndrome in a 59-year-old male.

Authors:  Russell Gollard; Syed Rahman; Ramalingam Ratnasabapathy
Journal:  Acta Haematol       Date:  2012-10-26       Impact factor: 2.195

  8 in total
  2 in total

1.  Successful Treatment of Life-threatening Bleeding Caused by Acquired Factor X Deficiency Associated with Respiratory Infection.

Authors:  Satoshi Ichikawa; Kei Saito; Noriko Fukuhara; Yuya Tanaka; Yoonha Lee; Koichi Onodera; Yasushi Onishi; Hisayuki Yokoyama; Minami Fujiwara; Hideo Harigae
Journal:  Intern Med       Date:  2020-02-05       Impact factor: 1.271

2.  Successful Treatment of Factor X Deficiency in a Patient with Lymphoplasmacytic Lymphoma with Bendamustine Plus Rituximab Regimen: A Case Report and Literature Review.

Authors:  Tarinee Rungjirajittranon; Yingyong Chinthammitr; Chattree Hantaweepant
Journal:  J Blood Med       Date:  2021-10-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.